Sanofi, Merck Get FDA Approval for Vaxelis
December 26 2018 - 3:07PM
Dow Jones News
By Bowdeya Tweh
Sanofi SA (SAN.FR, SNY) and Merck & Co. (MRK) have received
approval from U.S. health regulators for their drug designed to
vaccinate children against diseases including tetanus, whooping
cough and polio, the drugmakers said Wednesday.
The Food and Drug Administration has approved Vaxelis for use in
a three-dose series of injections in children from 6 weeks old
through age 4. Vaxelis was developed to vaccinate children against
diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and
disease due to Haemophilus influenzae type B.
The companies said a commercial supply of Vaxelis won't be
available in the U.S. until 2020, but added they would work to
maximize production to ensure a sustainable supply of the drug.
Health regulators in Europe cleared Vaxelis to be sold in
certain European countries in 2016.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
December 26, 2018 15:52 ET (20:52 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024